Treatment Resistant Depression Novel Pathways
At Johnson & Johnson, we’re building a more inclusive and connected health system by supporting independent training and education initiatives. We are proud to provide grants that support eligible organizations in offering independent continuing medical education for healthcare professionals – including physicians, nurses, residents, and pharmacists – by enhancing their skills and knowledge in meeting the needs of patients and the community.
Requests for educational grants are evaluated consistent with appropriate internal and external guidelines and policies. We prioritize support in areas of therapeutic interest, and are particularly interested in initiatives that support communities facing barriers to equitable healthcare access and representation.
Mood – Targeting Novel Pathways in Depression
- Major Depressive Disorder (MDD) journey to Treatment Resistant Depression (TRD)
- Treatment Resistant Depression (TRD) in clinical practice: clinical presentation of patients with inadequate response to two oral antidepressants in the same depressive episode
- TRD: early patient identification & treatment initiation
- Primary care provider’s role in the early identification & treatment of TRD
- Collaborative and patient-centric approach for treatment decision making in TRD
- Mechanistic rationale to pharmacological treatment approaches
- Treatment approaches in TRD including interventional treatments
- Early use of newer antidepressants in TRD
- Strategies for preventing relapse in TRD, and the impact of relapse prevention
- Value of innovative treatments from the patient & societal perspective
- Impact MDD & TRD in communities and populations experiencing systemic inequities
- Insomnia as a symptom of MDD
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.